Lehn P, Sigaux F, Grausz D, Loiseau P, Castaigne S, Degos L, Flandrin G, Dautry F
Blood. 1986 Oct;68(4):967-70.
Low-dose interferon-alpha (IFN-alpha) therapy is consistently effective in the treatment of hairy cell leukemia (HCL). In two cases of resistance to IFN-alpha administration, we diagnosed variant HCL, a form of HCL with intermediate features between typical HCL and B cell prolymphocytic leukemia. We tried to distinguish variant and typical hairy cells (HCs) by Northern blot analysis of the oncogenes expressed in vivo. We report that variant HCs contain c-myc transcripts in contrast to typical HCs, whereas c-fos transcripts are detected in both cell types. We also report that the mRNA levels of c-myc are not modified in variant HCs by IFN-alpha treatment, whereas the level of c-fos mRNA is modulated in both types of HCs. Our findings suggest that the failure to modulate c-myc expression in vivo might indicate the limits of low-dose IFN-alpha therapy.
低剂量α干扰素（IFN-α）疗法在毛细胞白血病（HCL）的治疗中始终有效。在两例对IFN-α治疗耐药的病例中，我们诊断为变异型HCL，这是一种具有典型HCL和B细胞原淋巴细胞白血病之间中间特征的HCL形式。我们试图通过对体内表达的癌基因进行Northern印迹分析来区分变异型和典型毛细胞（HC）。我们报告，与典型HC相比，变异型HC含有c-myc转录本，而在两种细胞类型中均检测到c-fos转录本。我们还报告，IFN-α治疗不会改变变异型HC中c-myc的mRNA水平，而两种类型的HC中c-fos mRNA水平均受到调节。我们的研究结果表明，体内未能调节c-myc表达可能表明低剂量IFN-α治疗的局限性。
